Angiopoietin-like 3 antibody rivocibart for homozygous familial hypercholesterolemia

28 August 2026 (16:15 - 16:30)

Organised by:

Video

Slides

Sign in for access options

About the speaker

Professor Daoquan Peng

The Second Xiangya Hospital of Central South University, Changsha (China)

3 More presentations in this session

Presentation thumbnail

Durability of Effects of CTX310, a CRISPR-Cas9 Gene Editing Targeting ANGPTL3

Associate Professor L. Laffin (Cleveland, US)

Presentation thumbnail

AAV8-mediated gene therapy for homozygous familial hypercholesterolemia

Doctor T. Li (Xi'an, CN)

Presentation thumbnail

Extremely Long Duration Lp(a) Reduction Following a Single Dose of Kylo-11: Final Data from a First-in-Human Study

Doctor A. Sarraju (Cleveland, US)

Access the full session

Session thumbnail

Late-Breaking Clinical Trials: rewriting cardiovascular disease on gene and molecular therapies

The Event

Event poster

ESC Congress 2026

28 August 2026 16:15 CET

You may be interested in

Congress Presentation

Ticalicibart monthly as add-on therapy to statins for nonfamilial hypercholesterolemia: the randomized, phase 3 TIMER trial

28 August 2026

Congress Presentation

Coronary CT Angiography to Guide Lipid Management in an Asymptomatic Community-Based Population

28 August 2026

Congress Presentation

SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study

1 September 2024

Congress Presentation

Efficacy and safety of pemafibrate in patients with statin-intolerant hypercholesterolemia: results from a 12-week, randomized, double blind, placebo-controlled, phase 3 trial

31 August 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources